Multiple Sclerosis Drugs - EU-27

EU-27

In the EU-27, the Multiple Sclerosis Drugs market is anticipated to witness a substantial increase in revenue, with projections estimating it to reach US$2.70bn by the year 2024.
Moreover, the market is expected to display a steady growth rate of 0.80% annually from 2024 to 2029, resulting in a market volume of US$2.81bn by the end of 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in this market, reaching a staggering US$11,770.00m in 2024.
In Germany, the market for Multiple Sclerosis Drugs is experiencing a surge in demand due to a growing patient population and advancements in treatment options.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in EU-27 has been experiencing steady growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis (MS) in the EU-27 region have been increasingly demanding more effective and convenient treatments. They prefer drugs that have fewer side effects and can be administered orally, as opposed to injections. Furthermore, patients are also seeking treatments that can slow down the progression of the disease and improve their quality of life.

Trends in the market: The MS drugs market in EU-27 has been growing steadily due to the increasing prevalence of MS in the region. The market has been witnessing a shift towards oral treatments, as they offer greater convenience to patients. The market has also been experiencing increased competition, with several new drugs entering the market in recent years. This has led to price competition among drug manufacturers, resulting in lower prices for MS drugs.

Local special circumstances: The MS drugs market in EU-27 is highly regulated, with strict rules and regulations governing the approval and distribution of drugs. This has led to a slower approval process for new drugs, which can delay their entry into the market. Additionally, the market is highly fragmented, with different countries having different regulations and healthcare systems. This can make it challenging for drug manufacturers to launch their products in multiple countries.

Underlying macroeconomic factors: The MS drugs market in EU-27 is influenced by several macroeconomic factors, such as the aging population and increasing healthcare expenditure. The aging population in the region has led to a higher prevalence of MS, which has driven demand for MS drugs. Additionally, increasing healthcare expenditure has led to greater investment in research and development of new MS drugs. However, the market is also impacted by the ongoing economic uncertainty in the region, which has led to budget constraints in some countries and may limit access to MS drugs for some patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.